Back to Search Start Over

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Authors :
Conteduca, Vincenza
Jayaram, Anuradha
Romero-Laorden, Nuria
Wetterskog, Daniel
Salvi, Samanta
Gurioli, Giorgia
Morales Barrera, Rafael
Institut Català de la Salut
[Conteduca V] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. [Jayaram A] Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. The Royal Marsden NHS Foundation Trust, London, UK. University College London Cancer Institute, London, UK. [Romero-Laorden N] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain. Hospital Universitario La Princesa, Madrid, Spain. [Wetterskog D] Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. University College London Cancer Institute, London, UK. [Salvi S, Gurioli G] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. [Morales R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
Hospital Universitari Vall d'Hebron
Source :
Scientia, Recercat. Dipósit de la Recerca de Catalunya, instname, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Publication Year :
2019
Publisher :
Elsevier, 2019.

Abstract

Càncer de pròstata; Receptor d'andrògens; Docetaxel Cáncer de próstata; Receptor de andrógenos; Docetaxel Prostate cancer; Androgen receptor; Docetaxel Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR]=1.61, 95% confidence interval [CI]=1.08-2.39, p=0.018), but not PFS (HR=1.04, 95% CI 0.74-1.46, p=0.8) or PSA response (odds ratio=1.14, 95% CI=0.65-1.99, p=0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, p

Subjects

Subjects :
Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids::Docetaxel [CHEMICALS AND DRUGS]
hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de andrógenos [COMPUESTOS QUÍMICOS Y DROGAS]
Pròstata - Càncer
Metàstasi
compuestos orgánicos::hidrocarburos::hidrocarburos cíclicos::hidrocarburos alicíclicos::cicloparafinas::ciclodecanos::taxoides::docetaxel [COMPUESTOS QUÍMICOS Y DROGAS]
neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES]
Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Androgen Antagonists::Androgen Receptor Antagonists [CHEMICALS AND DRUGS]
Antiandrògens
Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant [DISEASES]

Details

Language :
English
ISSN :
20141912
Database :
OpenAIRE
Journal :
Scientia, Recercat. Dipósit de la Recerca de Catalunya, instname, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Accession number :
edsair.dedup.wf.001..2364dc5c681174868c5724209f2e98bb

Tools

Authors Abstract Subjects Details